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Background: Health-related stigma adds to the physical and economic burdens experienced by people suffering
from neglected tropical diseases (NTDs). Previous research into the NTD podoconiosis showed significant stigma
towards those with the disease, yet no formal instrument exists by which to assess stigma or interventions to
reduce stigma. We aimed to develop, pilot and validate scales to measure the extent of stigma towards
podoconiosis among patients and in podoconiosis-endemic communities.
Methods: Indicators of stigma were drawn from existing qualitative podoconiosis research and a literature review
on measuring leprosy stigma. These were then formulated into items for questioning and evaluated through a
Delphi process in which irrelevant items were discounted. The final items formed four scales measuring two distinct
forms of stigma (felt stigma and enacted stigma) for those with podoconiosis and those without the disease. The
scales were formatted as two questionnaires, one for podoconiosis patients and one for unaffected community
members. 150 podoconiosis patients and 500 unaffected community members from Wolaita zone, Southern
Ethiopia were selected through multistage random sampling to complete the questionnaires which were interview-
administered. The scales were evaluated through reliability assessment, content and construct validity analysis of
the items, factor analysis and internal consistency analysis.
Results: All scales had Cronbach’s alpha over 0.7, indicating good consistency. The content and construct validity
of the scales were satisfactory with modest correlation between items. There was significant correlation between
the felt and enacted stigma scales among patients (Spearman’s r = 0.892; p < 0.001) and within the community
(Spearman’s r = 0.794; p < 0.001).
Conclusion: We report the development and testing of the first standardised measures of podoconiosis stigma.
Although further research is needed to validate the scales in other contexts, we anticipate they will be useful in
situational analysis and in designing, monitoring and evaluating interventions. The scales will enable an evidence-
based approach to mitigating stigma which will enable implementation of more effective disease control and help
break the cycle of poverty and NTDs.
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Stigma is increasingly being recognised as an obstacle to
good health and a barrier to accessing healthcare.
Health-related stigma affects the life chances of indivi-
duals, increasing their exposure to risks and limiting ac-
cess to protective factors, potentially adding to their
burden of disease or disability [1]. Assessing levels of
stigma is therefore becoming increasingly important for* Correspondence: franklin.hannahmay@gmail.com
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reproduction in any medium, provided the orpublic health, particularly with regard to guiding policy,
designing and evaluating interventions, and advocacy
work. Research is required to both clarify the nature of
the stigma burden and develop and test strategies for
mitigating problematic stigma [2].
Health-related stigma is typically characterised by so-
cial disqualification of individuals and populations who
are identified with particular health problems and judged
as a result of that condition [2]. This stigma can be di-
vided into enacted stigma and felt stigma [3]. Enacted
stigma refers to the actual experience of discrimination,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of employment, and prejudicial attitudes [4]. In contrast,
felt (or perceived) stigma refers to fear of this enacted
stigma [5]. This might involve individuals with a
stigmatised condition purposely avoiding social situa-
tions to reduce opportunities for enacted stigma [3].
Further still, social judgement may not only be antici-
pated but internalised, so those who are stigmatised de-
value themselves, and in turn feel a sense of shame [6].
Both felt and enacted stigma can pose threats to the
self-esteem and security of those with certain diseases or
symptoms [5] as well as further impacting on their
health status.
The stigma surrounding neglected tropical diseases
(NTDs) is particularly detrimental, fuelling insecurities
which keep people trapped in a vicious cycle of poverty
[6,7]. Podoconiosis is an example of an NTD caused by
long-term exposure of bare feet to irritant volcanic soils
with symptoms which include swelling of the lower leg
and skin thickening. The stigma attached to the disease
limits social and economic opportunities for affected in-
dividuals and thwarts efforts to effectively treat and
prevent podoconiosis, negatively impacting on health-
seeking behaviour and acting as a barrier to appropriate
care from health workers [8-10].
In order to implement effective NTD control pro-
grammes, gauging the nature of stigma is required,
alongside assessments of the physical environment and
medical resources available [7]. Instruments to measure
stigma can be used to assess the magnitude of NTD-
related stigma in a community and identify which mani-
festations of stigma are most profound. Understanding
the dynamics of podoconiosis stigma will enable the
design of more effective interventions: the data collected
may in future be used to evaluate and tailor stigma
reduction strategies specific to community needs.
Although stigma related to podoconiosis has been ex-
plored quantitatively [8,9] and qualitatively [10,11], there
is no validated tool to measure stigma. In addition, pre-
vious research did not differentiate between felt stigma
and enacted stigma. The purpose of this study was
therefore to develop, pilot and validate a scale to mea-
sure the extent of stigma towards podoconiosis, drawing
from other NTD stigma scales and existing research on
podoconiosis.
Methods
Development of the study tool
We planned to include items measuring felt stigma and
enacted stigma at both the family and community level
to encompass stigma found in day-to-day interactions
and in wider social participation. We also aimed to
include both those affected by podoconiosis and un-
affected community members.Potential items to be included in the scales were iden-
tified by analysing the findings of studies investigating
community knowledge, attitudes and practices towards
individuals with podoconiosis [8-11]. Other potential
items were identified from a literature review on mea-
suring stigma towards leprosy [12], another highly
stigmatised NTD with symptoms that are hard to
conceal, like podoconiosis. Since individuals with
podoconiosis face similar exclusionary social treatment
to those with leprosy, commonly used items in leprosy
stigma assessments were also included in this study.
Potential items were then grouped according to
the WHO International Classification of Functioning,
Disability and Health (ICF) [13]. Of the nine domains,
leprosy stigma had greatest impact on mobility, domestic
life, interpersonal interactions and relationships, major
life areas, and community, social and civic life [12].
Again, existing qualitative research [10,11] has demon-
strated the effect podoconiosis stigma has on these
areas, so these formed the basis through which stigma
was assessed (Table 1).
Two structured 50-item pilot scales were produced
based on the indicators in Table 1, one for podoconiosis
patients and one for unaffected community members.
The scales generated were first evaluated through a
Delphi process in which six people with expertise in the
area of podoconiosis were asked to rate the relevance of
items included in the preliminary scales. After several
discussions, an exclusion consensus was reached and
items considered irrelevant were rejected. The inclusion
criteria decided by the research team were that each
item had to be universal (applicable in different cultural
contexts and across different groups such as age, marital
status and social class); had to measure stigma (rather
than confidence, or self-esteem) and could be clearly
categorised as felt or enacted stigma. On the basis of
these criteria, 18 items were excluded from the prelimi-
nary podoconiosis patient scales.
The scales agreed for testing were formatted as ques-
tionnaires containing both positively and negatively
framed items to address response set bias, and translated
into both the Ethiopian national language (Amharic) and
the local language (Wolaitigna) and back translated into
English to check for consistency.
Drawing from responses used in scales to measure
stigma towards onchocerciasis [14,15] participants were
asked to respond with either ‘yes’, ‘possibly’, ‘uncertain’ or
‘no’ to each item on the questionnaire. A score of 3 was
given for a ‘yes’ response to an item on the scale, 2 for
‘possibly’, 1 for ‘uncertain’ and 0 for ‘no’. A mean value
for each item on the scales is then calculated from the
participant responses ranging from 0 indicating low
stigma to 3 indicating high stigma. This scoring system,
and the scales themselves, was developed to aid
Table 1 Indicators of podoconiosis stigma in three domains
Domain 1: Interpersonal interactions (domestic life, family/
neighbourhood relationships)
Domain 2: Major
life areas
Domain 3: Community, social and civic life
• Buying items at market • Employment • Leadership and decision making
• Eating/living separately • Marriage • Participation in community affairs, public events
and social organisations
• Interactions with family, friends, neighbours and health
professionals
• Isolation from others
• Shame/embarrassment
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no stigma with a clear numerical cut off point.
Participant selection
Study area and population
The scales were piloted in Wolaita zone, Southern
Ethiopia, which has a population of around 1.53 million,
88.3% living in rural areas, the majority working as sub-
sistence farmers [16]. Wolaita zone was chosen because
of the high prevalence of podoconiosis (5.5%) [17], and
the community’s acceptance and responsiveness to pre-
vious podoconiosis research. The Mossy Foot Treatment
and Prevention Association (MFTPA, a non-government
organisation specialising in podoconiosis prevention and
care) also provides a contact base for over 35,000
podoconiosis patients [18].
Sample size
Assumptions used in the sample size estimate were
drawn from Brieger’s study measuring onchocerciasis
(another NTD) stigma in Western Nigeria (Briefer et al.,
1998), and the desired size of reduction in stigma level
towards podoconiosis patients were an intervention to
be introduced.
We used a mean stigma score of 17 and standard de-
viation of 10 (Brieger’s 13 item, 39 point scale), and the
following equation:
Use n ¼ uþ vð Þ
2 SD12 þ SD22ð Þ
mean1 mean2ð Þ2
(where u = 1.28 for power of 90%; v = 1.96 for 2-sided sig-
nificance level of 5%; SD1 = 10, SD2 = 10) (Kirkwood 1988).
A series of sample sizes were calculated based on a
range of stigma reductions anticipated. A sample size of
150 podoconiosis patients was calculated to give 90%
power to detect a stigma reduction of 20–25%. Less dra-
matic reduction in stigma level was anticipated in the
non-affected community, and 500 community controls
were calculated to give 90% power to detect a reduction
of 10–15%. A sample of 500 unaffected community
members and 150 podoconiosis patients is also adequate
to enable factor analysis and thereby validate the scales,based on item to case ratio recommendations for factory
analyses. Costello and colleagues recommend an optimal
sample of 20 individuals to one item [19].Sampling technique
A two stage sampling was used to identify 150 podoconiosis
patients in Wolaita Zone. First, five of fourteen active clinic
sites of the MFTPA were randomly selected. Systematic
sampling was then employed using the patient list at each
clinic site to select 30 patients. Any participants who might
have been experiencing stigma for other health afflictions
such as leprosy or other visible skin diseases were excluded.
Unaffected community members were identified
through multistage stratified random sampling. Firstly
four weredas (districts) were randomly identified and
within each wereda, two kebeles (smallest administrative
unit) or Peasant Associations (PAs) were randomly se-
lected. Within each of the weredas, 125 adult (≥ 18 years)
household heads were systematically selected from the
list obtained from the two kebele administrative offices
to make a total sample size of 500 community members.
If any of those individuals identified themselves as ha-
ving podoconiosis, they were excluded from the sample.Data collection
Due to the low literacy rate of participants the question-
naire was interview-based. Six data collectors were fully
briefed on the purpose of study, the eligibility criteria for
participants and given training on how to request con-
sent and administer the questionnaires.
Data were collected in May 2011. Podoconiosis patients
were interviewed in a private area of the clinic they were
approached in. Non-affected community members were
interviewed in a private area of their home.
All participants were asked to give their responses
according to a 12 month time frame (‘since the start of
the last rainy season. . .’) in order to measure recent ac-
counts and perceptions of stigma.When administering
the questionnaire, the participant’s age, gender and edu-
cation level were recorded, and for podoconiosis patients
their disease stage was also noted for further analysis.
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Special attention was given to dealing with the sensitive
topic of stigma when obtaining informed consent from
participants. Following guidance from early studies of the
ethics of approaching this community [20], podoconiosis
patients were first asked to participate by MFTPA staff with
whom they were familiar, before official consent was
obtained by data collectors.
Information sheets and consent forms were inappli-
cable in this particular setting due to the low-literacy
level of participants. Instead, the purpose of the study
was explained orally, in the style of a conversation rather
than reading out an information sheet, and potential
participants gave their consent verbally in front of a wit-
ness as confirmation. Ethical approval for this study was
given by the IRB of Wolaita Sodo University in Ethiopia.
Data analysis
Before analysis, we decided that since felt stigma and
enacted stigma represent two distinct dimensions, they
should be assessed through two independent scales. Four
scales were therefore analysed in total: a podoconiosis
patient felt stigma scale, a community felt stigma scale, a
podoconiosis patient enacted stigma scale and a commu-
nity enacted stigma scale.
The scales were evaluated through reliability assess-
ment, content and construct validity analysis of the
items, factor analysis and internal consistency analysis.
Reliability assessment
Reliability was assessed through consistency analysis
using Cronbach’s alpha. An alpha of 0.7 to 0.9 was con-
sidered good consistency [21]. The impact of deleting an
item on overall consistency was also assessed, with the
aim of discarding an item whenever its deletion led to a
noticeable improvement in the overall consistency of the
rest of the items.
Content and construct validity
Content validity was examined using Spearman’s correl-
ation coefficients. Construct validity was analysed using ex-
ploratory factor analysis (FA) with principal components
analysis (PCA). Separate factor analyses were performed for
felt and enacted stigma for both podoconiosis patients and
the community. The first round of un-rotated factor ana-
lyses yielded Scree Plots to determine the number of factors
underlying the respective stigma dimensions. To find the
best fit to the data, orthogonal and non-orthogonal analyses
were also conducted. Factor loadings of more than 0.4 were
considered satisfactory for the patient and community
questionnaires [19]. Findings of the PCA were further
validated by split-half reliability analysis, in which the two
random halves of the data were expected to provide simi-
lar factor solutions. Following recommendations [22,23],factors generated by the PCA were extracted as valid
if at least two of the following criteria were met: (1)
eigenvalues were equal to or greater than the ran-
domly generated factors from Horn’s parallel ana-
lysis; (2) the scree (Cattel’s) test was passed and; (3)
eigenvalues of equal or more than unity [24,25].
For analysis on any given variable, cases were
excluded if data on that variable were missing. Total
scores were only calculated if a case had responded
to more than 50% of the items. SPSS 15.0 was used
for reliability and validity analysis, while Monte-Carlo PA
software was used for parallel analysis. An alpha of 0.05 or
less was considered significant.
Results
Participant demographics
In the podoconiosis patient sample, all 150 question-
naires were used in analysis. Of the 500 community
sample, 17 questionnaires were either incomplete or in-
adequately completed, and were excluded from analysis,
leaving a total sample of 483 (Table 2).
Podoconiosis patients felt stigma scale
In the factor analysis, one item from the preliminary pa-
tient questionnaire was rejected because it had loadings
below our criterion value of 0.4.
There existed a good consistency between items: and
Cronbach's alpha was 0.955. No item significantly im-
proved the level of consistency when deleted. There was
modest correlation between items, but no pair of corre-
lations had a value more than 0.9.
PCA revealed a single factor model explaining
61.5% of the data. The first factor, with an eigen
value of 9.2, explained about 61.5% of the variance,
while the second, with an eigen value of 1.03,
explained about 6.9% (Table 3). The first factor met
the criterion value generated by parallel analysis, and
passed the scree test. The final felt stigma scale for
patients comprised 15 items:
Interpersonal interactions
1. Have you avoided taking part in labour or other
activities which require group involvement with
unaffected people?
2. Have you tried to use household utensils separately
from other family members?
3. Have you felt your family are proud of you?
4. Have you continued seeing and spending time with
your (unaffected) friends?
5. Have you avoided asking neighbours for help, or to
borrow items because of your condition?
6. Have you tried to kill yourself because of the
demeaning treatment you receive as a result of
your condition?
Table 2 Participant demographics
Variables Category Podoconiosis patients Unaffected community members
Number (%) Number (%)
Sex Female 81 (54) 204 (42.2)
Male 69 (46) 279 (57.8)
Age <25 23 (15.3) 57 (11.8)
25–34 35 (47) 146 (30.2)
35–49 47 (31.3) 209 (43.3)
> = 50 45(30) 71 (14.7)
Education Illiterate 98 (65.3) 207 (42.9)
Literate 52 (34.7) 276 (57.1)
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because of the way you are treated as a result of
your condition?
Major life areas
1. Have you avoided any invitation to be employed for
wage labour/job fearing stigma in the work place?
2. Have you feared unaffected individuals may feel
uncomfortable working with you because of your
condition?
3. Have you avoided marriage to an unaffected person
fearing mistreatment after marriage?
4. Have you feared that marriage with an unaffected
person may end in divorce?
5. Do you feel your condition has affected your other
family member’s chances of marrying?
Community, social and civic life
1. Do you think that your condition deprives you from
playing a leadership role in the community?
2. Have you avoided visiting public places like church,
school or market?ble 3 Patient data: factor extraction decision¥
mponents Eigen
value
Total
variance
(%)
PA random ei
lt stigma
9.23 61.5 1.59 (0.07)
1.03 6.9 1.45 (0.05)
0.81 5.0 1.34 (0.04)
acted stigma
10.7 63.0 1.63 (0.07)
1.04 6.1 1.49 (0.05)
0.96 5.6 1.39 (0.04)
he non rotated factor analysis provided the best fit to the data; Kaiser-Meyer-Olk
gmas respectively; All anti-image matrices measures of sampling adequacy (MSA)
< 0.001 for both scales; ‘Yes’, indicates criteria is fulfilled, ‘No’ indicates otherwise.
st recommends extracting factors above the elbow of the scree plot. PA: parallel3. Have you felt able to move around the community
freely (without being stared at, pointed at or people
noticing you?)
Podoconiosis patients enacted stigma scale
Cronbach's alpha was 0.94, indicating good consistency
between items. No item significantly improved the level
of consistency when deleted. There was modest correl-
ation between items, but no pair of correlations had a
value more than 0.9.
PCA produced a single factor model explaining 63.0%
of the variance. The first factor had an eigen value of
10.7 and explained about 63.0% of the variance, while
the second one had an eigen value of 1.04 and explained
about 6.1% of the variance (Table 3). The first factor was
above the criterion value generated by parallel analysis,
and passed the scree test. The final enacted scale for pa-
tients is made up of 17 items:
Interpersonal interactions
1. Has anyone in your neighbourhood deterred you
from taking part in group activities?Extraction criteria Decision
to
extract
gen value (SD) Kaiser Scree test
Yes Yes Yes Yes
No Yes No No
No No No No
Yes Yes Yes No
No Yes No No
No No No No
in sampling adequacy equals 0.929 and 0.944 for perceived and enacted
were near or greater than 0.9 for both scales; Bartlett’s test of sphericity,
Kaiser recommends extracting factors with eigen value of ≥1; Scree (Cattel’s)
analysis.
Franklin et al. BMC Public Health 2013, 13:298 Page 6 of 9
http://www.biomedcentral.com/1471-2458/13/2982. Have your family members avoided sharing
household utensils with you?
3. Have friends been visiting you less or
spending less time with you because of your
condition?
4. Have you received insults from others regarding
your foot?
Major life areas
1. Is there an example where you or another person
you know has been denied a job opportunity
because of the condition?
2. Have you or another person you know been forced
to leave a job because of the condition?
3. Have you or another person you know been
mistreated at your work place due to the condition?
4. Have you or another person you know been forced
to dissolve marriage plans because of the condition?
5. Have you or another person you know experienced
divorce because of the condition?
6. Has your condition made it difficult for an
unaffected member of your family to marry?
Community, social and civic life
1. Is there an example where you or another person
you know has been denied the chance of a
leadership role due to the condition?
2. Is there an example where you or another person
you know have been denied the chance to make
decisions in community matters?
3. Have people ignored you, talked over you or told
you to be quiet because of your condition?
4. Have you or another person you know been
welcomed (by unaffected people) while attending
church, school or other community meeting places?
5. Is there an example where you or another
person you know have been treated in isolation
at a social event?
6. Is there an example where you or another
person you know have not been invited to
appear at public places?
7. Is there an example where you or another person
you know has been stared or pointed at when
attending a social event?
Unaffected community felt stigma scale
In the factor analysis, one item from the preliminary
community questionnaire was rejected because it had
loadings below our criterion value of 0.4.
Cronbach’s alpha was 0.85, indicating good consistency
between items. No item significantly improved the level
of consistency when deleted. There was modest amount
of correlation between items, but no pair of correlations
had a value more than 0.9.PCA provided a four factor model explaining 49.4% of
the data. The first factor had an eigen value of 5.8 and
explained about 24% of the variance, while the second
had an eigen value of 2.8, and explained about 11.7%.
These were above the criterion value generated by paral-
lel analysis, and fulfil the scree test criteria (Table 4).
These analyses were also valid when re-run using ran-
dom halves of the dataset. The final felt stigma scale for
the community comprised 24 items:
Interpersonal interactions
1. Have you seen or heard of someone with this
condition who fears bringing items to the market
thinking they may not be sold?
2. Have you seen or heard of someone with this
condition hesitating to visit a health centre fearing
that health professionals may pity them?
3. Have you seen or heard about the children of
someone with this condition dropping out school?
4. Have you seen or heard of someone with this
condition avoiding taking part in group activities
such as labour with unaffected people?
5. Have you seen or heard of someone with this
condition trying to use household utensils separately
from other family members?
6. Have you seen or heard of someone with this
condition avoiding preparing food for other
family members?
7. Does someone with this condition feel their family is
proud of them?
8. Do you think someone with this condition is happy
seeing or spending time with unaffected friends?
9. Do you think someone with this condition feels
comfortable asking neighbours for help, or to
borrow items?
10.Have you seen or heard of someone with this
condition who has committed or tried to commit
suicide?
11.Have you seen or heard of someone with this
condition who has changed or tried to change the
place where they live?
Major life areas
1. Have you seen or heard of someone with this
condition who feels uncomfortable working with
unaffected individuals?
2. Do you think someone with this condition feels they
are as capable or productive as others?
3. Have you seen or heard of someone with this
condition who has avoided marrying an
unaffected person fearing mistreatment after
marriage?
4. Does someone with this condition feel confident
asking an unaffected person for marriage?
Table 4 Community data: factor extraction decision¥
Components Eigen
value
Total
variance
(%)
Extraction criteria Decision
to
extract
PA random eigen value (SD) Kaiser Scree test
Felt stigma
1 5.79 24.10 1.42 (.04) Yes Yes Yes Yes
2 2.81 11.7 1.35 (.03) Yes Yes Yes Yes
3 1.75 7.3 1.30 (.02) Yes Yes Yes Yes
4 1.50 6.3 1.26 (.02) Yes Yes No Yes
Enacted stigma
1 7.84 34.1 1.4075 (.04) Yes Yes Yes Yes
2 1.97 8.6 1.3411 (.04) Yes Yes Yes Yes
3 1.27 5.5 1.2915 (.02) No Yes No No
4 1.20 5.2 1.2473 (.02) No Yes No No
¥ The non rotated factor analysis provided the best fit to the data; Kaiser-Meyer-Olkin sampling adequacy equals 0.85 and 0.90 for perceived and enacted stigmas
respectively; All anti-image matrices measures of sampling adequacy (MSA) were near or greater than 0.90 for both scales; Bartlett’s test of sphericity, p < 0.000 for
both scales; ‘Yes’, indicates criteria is fulfilled, ‘No’ indicates otherwise. Kaiser recommends extracting factors with eigen value of ≥1; Scree (Cattel’s) test
recommends extracting factors above the elbow of the scree plot. PA: parallel analysis.
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that marriage to an unaffected person might end
in divorce?
6. Do you think someone with this condition feels their
condition has affected other family member’s
chances of marrying?
Community, social and civic life
1. Do you think someone with this condition feels
comfortable participating in community affairs?
2. Is someone with this condition afraid to accept a
leadership offer or play a leadership role in the
community?
3. Do you think someone with this condition is afraid
to take part in decision making fearing their ideas
might be discredited?
4. Does someone with this condition feel confident
appearing at public places?
5. Have you seen or heard about someone with this
condition who has avoided visiting public places like
church, school or market?
6. Do you think that unaffected people and people with
this condition should be served separately in public
places?
7. Do you think someone with this condition fears
others will stare or point at them in public places?Unaffected community enacted stigma scale
Two items (one related to being interested in eating food
prepared by someone with podoconiosis and the other
concerning podoconiosis patients being welcomed at
community meeting places) were rejected from thepreliminary questionnaire because they had loadings
below our criterion value of 0.4.
Cronbach’s alpha was 0.91, indicating good consistency
between items. No item significantly improved the level
of consistency when deleted. There was modest amount
of correlation between items, but no pair of correlations
had a value more than 0.9.
PCA produced a two factor model explaining 42.6% of
the variance. The first factor, with an eigen value of 7.8,
explained about 34% of the variance, while the second,
with an eigen value of 1.96, explained about 8.6%. These
were above the criterion value generated by parallel ana-
lysis, and fulfil the scree test criteria (Table 4). These
analyses were also valid when re-run using random
halves of the dataset. The final enacted stigma scale for
the community is made up of 23 items:
Interpersonal interactions
1. Has someone with this condition selling items at
market been avoided?
2. Have you seen or heard of anyone with this
condition being pitied by a health professional?
3. Have you seen or heard of any children of someone
with this condition being mistreated by friends or
teachers at school?
4. Has someone with this condition been stopped from
taking part in group activities in your
neighbourhood?
5. Have people avoided sharing or borrowing
household utensils with someone with this
condition?
6. Have people avoided sitting near or sharing a seat
with someone with this condition?
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condition being mistreated by their family compared
to unaffected members?
8. Have you seen or heard about someone with this
condition being isolated by their friends, family
members or neighbours?
9. Have you seen or heard insults being called out to
someone with this condition?
Major life areas
1. Do you know of anyone who has not been offered a
job because of this condition?
2. Have you seen or heard of anyone who was forced
to leave their job because of this condition?
3. Have you seen or heard of anyone who has
been mistreated in the work place because of
this condition?
4. Have you seen or heard of anyone who has
avoided marriage with someone because they had
this condition?
5. Have you seen or heard of anyone who has been
divorced because of this condition?
6. Have you seen or heard of anyone who has been
mistreated by their by spouse due to this condition?
7. Have you seen or heard of someone where their
condition made it difficult for their unaffected family
members to marry?
Community, social and civic life
1. Has there been an example where someone has been
denied the chance of a leadership role because of
this condition?
2. Has there been an example where someone with this
condition has been denied the chance to make
decisions in community matters?
3. Has there been an example where someone with
this condition has not been listened too or
ignored when talking?
4. Has there been an example where someone with
this condition has not been invited to appear at
public places?
5. Has someone with this condition been isolated at a
social event you have attended?
6. Has someone with this condition been stared or
pointed at while attending a social event?
7. Have you experienced someone with this condition
being excluded from using public facilities, such as
public transport?
Discussion and conclusions
Strengths
We report the development and testing of the first
standardised measures of podoconiosis stigma. All scales
had Cronbach’s alpha over 0.7, indicating good internalconsistency. The construct and discriminant validity of
the scales were satisfactory with modest correlation be-
tween items. There was significant correlation between
the felt stigma scale and enacted stigma scale among pa-
tients (Spearman's r = 0.892; p = 0.000; N = 150) and
within the community (Spearman's r = 0.794; p = 0.000).
Four scales have been produced which may be used in-
dividually as single instruments to measure specific as-
pects of podoconiosis stigma for certain social groups,
or may be combined to gain a more extensive overview
of the level of stigma towards podoconiosis in a given
community. The tools assessed both felt and enacted
stigma across three domains which covered both public
and private settings. Items are framed in order to record
actual rather than hypothetical acts of stigma over a spe-
cific time frame which will aid comparison of the level
of stigma pre- and post-intervention.
The greatest strength of this study is that it will enable
an evidence based approach to mitigating stigma, identi-
fying specific areas to target based on the precise needs
of the community. As Hotez [7] points out, there is no
‘one size fits all’ method for stigma reduction.
Limitations
One potential limitation of the study is the effect of
social desirability bias which may have compromised
participants’ report of prejudicial attitudes and discri-
minatory behaviours, particularly since the questionnaires
were interview-based rather than self-administered. Given
the low literacy of the population, we had no alternative
but to use interviews to gather data, and we acknowledge
that this may have reduced the reliability of the findings.
The recruitment of podoconiosis patients through
MFTPA clinics may have introduced selection bias, pos-
sibly resulting in exclusion of the most stigmatised pa-
tients who may not have reached these clinics.
The scales require further testing in other contexts in
order to validate them. Correlations between these scales
and others measuring variables related to stigma (such
as self-esteem and depression) or quality of life might
also be assessed.
Future uses of the scales
The scales developed as a result of this study will in-
crease understanding of the dynamics of podoconiosis
stigma and in turn, enable the design of more effective
reduction strategies [2,26].
We envisage the scales’ primary function to be in si-
tuational analysis where they can be used to assess the
state of the population before intervention. Through use
of the scales, areas of stigma which are most profound
and those social groups which are particularly affected
by stigma can be identified. The data collected can then
be used in the preparation and planning of stigma
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to monitor and evaluate stigma interventions and to
compare the efficacy of different strategies [26].
The four scales will also benefit future research on
podoconiosis stigma and in turn, prevention and treat-
ment of the disease as a whole. Furthermore, the scales
can be used to compare stigma intensity between differ-
ent groups or communities and discover factors that in-
crease the risk of stigmatisation from podoconiosis.
The ability to quantify podoconiosis stigma will help
justify interventions to reduce it and mobilise further ac-
tion [26]. Data produced by the scales can strengthen
the case of people involved in advocacy on behalf of
those stigmatised as a result of podoconiosis, such as the
MFTPA. The information collected can be used to ge-
nerate momentum towards tackling podoconiosis and
highlight the severity of the stigma burden, helping to
bring podoconiosis to government attention as a public
health issue.
In conclusion, we have developed four reliable and
valid scales to measure stigma towards podoconiosis and
guide interventions targeted towards reducing the
burden. Continued research that documents the impact
of NTD stigma on health-seeking behaviour and disease
control is required. The development of scales to assess
stigma are particularly valuable when applied to NTDs
since the stigma associated with diseases such as
podoconiosis compound the effects of poverty. Collecting
data that can guide policies and programs which seek to
mitigate the constraints of stigma allow individuals to
relieve themselves of the conditions that cause NTDs
to persist.
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